Redeye: Iconovo Q3 - Lower sales and costs than anticipated
Redeye provides an update following Iconovo’s Q3 report. While the company reported no sales for the quarter, costs were also lower than anticipated. The report does not significantly affect our investment case; however, we believe the upcoming ICOpre deal appears to be nearing completion, which could serve as a key catalyst for the share price and is crucial for extending Iconovo’s cash runway. Based on the report, we have adjusted our sales and cost estimates, leading to an updated fair value range.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/